Skylark Bio is a clinical-stage biopharmaceutical company developing gene therapy solutions that address the root causes of hearing impairments, with the goal of enhancing or even restoring natural communication. Skylark Bio's first clinical program, SKY-GjB2-001, is a potentially first- and best-in-class gene therapy employing targeted micro-dose given as a single unilateral intracochlear administration for the one-time treatment of pediatric deafness associated with GJB2-mutation.